The hepatitis B virus (HBV), family Hepadnaviridae, is one of most relevant human pathogens. HBV origins are enigmatic, and no zoonotic reservoirs are known. Here, we screened 3,080 specimens from 54 bat species representing 11 bat families for hepadnaviral DNA. Ten specimens (0.3%) from Panama and Gabon yielded unique hepadnaviruses in coancestral relation to HBV. Full genome sequencing allowed classification as three putative orthohepadnavirus species based on genome lengths (3,149-3,377 nt), presence of middle HBV surface and X-protein genes, and sequence distance criteria. Hepatic tropism in bats was shown by quantitative PCR and in situ hybridization. Infected livers showed histopathologic changes compatible with hepatitis. Human hepatocytes transfected with all three bat viruses cross-reacted with sera against the HBV core protein, concordant with the phylogenetic relatedness of these hepadnaviruses and HBV. One virus from Uroderma bilobatum, the tent-making bat, cross-reacted with monoclonal antibodies against the HBV antigenicity determining S domain. Up to 18.4% of bat sera contained antibodies against bat hepadnaviruses. Infectious clones were generated to study all three viruses in detail. Hepatitis D virus particles pseudotyped with surface proteins of U. bilobatum HBV, but neither of the other two viruses could infect primary human and Tupaia belangeri hepatocytes. Hepatocyte infection occurred through the human HBV receptor sodium taurocholate cotransporting polypeptide but could not be neutralized by sera from vaccinated humans. Antihepadnaviral treatment using an approved reverse transcriptase inhibitor blocked replication of all bat hepadnaviruses. Our data suggest that bats may have been ancestral sources of primate hepadnaviruses. The observed zoonotic potential might affect concepts aimed at eradicating HBV.
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evolution | zoonosis | virome | metagenomics | reverse genetics M ore than 40% of the human population has been infected with the hepatitis B virus (HBV), giving rise to 240 million chronic HBV carriers and ca. 620,000 HBV-associated deaths annually (1) . A prophylactic vaccine containing the small HBV genotype A2 surface antigen (SHB) is part of the worldwide Expanded Program on Immunization. Because of the general success of SHBs-based vaccination, global eradication of HBV has been considered achievable (2, 3) . Potential for the virus to be eradicated is supported by the fact that there are no known animal reservoirs. However, recent studies addressing the distribution of pathogens related to human viruses in wild animals, including mumps-and measles-related viruses in bats, have uncovered surprising putative novel reservoirs for human-pathogenic viruses (4).
Significance
Hepatitis B virus (HBV) is the prototype hepadnavirus; 40% of humans have current or past infection. In a global investigation of viral diversity in bats, we discovered three unique hepadnavirus species. The relatedness of these viruses to HBV suggests that bats might constitute ancestral sources of primate hepadnaviruses. Infection patterns in bats resembled human infection with HBV. After resurrection from bat tissues, pseudotyped viruses carrying surface proteins of one bat hepadnavirus could infect human liver cells. HBV vaccination is probably not protective against these viruses, but viral replication could be blocked by a reverse transcriptase inhibitor used as an anti-HBV drug in humans. The potential of bat hepadnaviruses to infect humans should be considered in programs aimed at eradicating HBV.
HBV is the prototype species of the family Hepadnaviridae, which comprises two genera: the genus Orthohepadnavirus associated with mammals and the genus Avihepadnavirus associated with birds. Phylogenetic studies suggested the presence of HBV in humans for at least 15,000 y (5). Recent analyses of avihepadnaviral sequences integrated into the genomes of several avian species suggested a much older origin, dating back at least 19 million y (6) . No HBV genomic elements have so far been found in humans or other primates, preventing more precise estimates of the origins of primate HBV (i.e., human and nonhuman primate viruses). HBV strains can be divided into nine strictly humanassociated genotypes (A-I). Additional strains outside some of those human-specific clades are known in chimpanzees, gorillas, gibbons, and orangutans (7) . With sporadic exceptions (8) , these primate HBV strains do not infect humans. The closest relative to human or ape viruses has been found in captive woolly monkeys (Lagothrix lagotricha), a South American nonhuman primate species (9) . There are only three nonprimate orthohepadnaviruses, all being even less closely related to HBV. These viruses include woodchuck HBV from Eastern woodchucks (Marmota monax), Californian ground squirrel (Otospermophilus beecheyi) HBV, and arctic squirrel (Spermophilus parryi) HBV (10). These rodent hosts are endemic in circumscribed areas of North America, and their viruses are highly hostspecific and cannot infect human hepatocytes (11, 12) .
Within the ∼5,500 known terrestrial species of mammals, about 20% are bats. Close relatives of pathogenic human viruses have been described in bats over the last years, including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)-related coronaviruses (CoV) as well as filoviruses, such as Ebola-and Marburgvirus (13, 14) . Among the multiple factors that facilitate virus evolution within and transmission from bats are their longevity, migratory activity, large and dense roosting communities, and close social interaction (14) . We have analyzed earlier the role of bats in the evolution of pathogenic viruses using very large globally and phylogenetically comprehensive samples of animals (4, 15) . In this study, we detected highly diversified bat hepadnaviruses capable of infecting human hepatocytes through the HBV-specific human receptor but not neutralized by SHBs vaccineinduced antibodies.
Results HBV Detection. Bats were sampled between 2002 and 2011 in Panama, Brazil, Gabon, Ghana, Germany, Papua New Guinea, and Australia (Fig. 1 ). These specimens represented 54 different species and 11 of 18 extant bat families (Table S1 ). Serum and liver specimens from 3,080 individual bats were individually tested using two broadly reactive and highly sensitive nested PCR assays. The sensitivities of these PCR assays at 95% probability of detection were 41.3 (95% confidence interval = 29.7-75.9) and 64.7 (95% confidence interval = 47.3-112.9) international units/mL blood ( Fig. S1 and Table S2 ). Liver specimens only were available for all 199 bats sampled in Brazil, and all other 2,881 specimens were sera. In 10 of 3,080 specimens (0.3%; all sera), HBV-related sequences were detected. Positive specimens stemmed from three different bat species. Among New World bats, 5 of 54 (9.3%) Uroderma bilobatum specimens from Panama tested positive. Among Old World bats, 4 of 51 Hipposideros cf. ruber specimens (7.9%) and 1 of 16 Rhinolophus alcyone specimens (6.3%) from Gabon contained HBV-like sequences. Fig. 1 shows the distribution areas of these bat species in gray.
Genome Organization. Full virus genome sequences were determined from all positive specimens of H. cf. ruber, the single specimen of R. alcyone, and four specimens of U. bilobatum (GenBank accession nos. KC790373-KC790381). The bat viruses formed three different lineages on preliminary phylogenetic inspection. Viruses from H. cf. ruber were collectively termed roundleaf bat HBV (RBHBV), the virus from R. alcyone was designated horseshoe bat HBV (HBHBV), and viruses from U. bilobatum were collectively termed tent-making bat HBV (TBHBV). Virus designations were chosen according to the designation of other nonhuman hepadnaviruses based on the common names of their hosts [e.g., Woolly monkey HBV (WMHBV)], and they are detailed in Fig. S2A . The genome organization and size of the putative open reading frames (ORFs) were compared with all other known hepadnaviruses (Fig. S2B ). RBHBV genomes comprised 3,368 nt, with a total of 12-18 (0.4-0.5%) nucleotide exchanges between each other. HBHBV comprised a genome of 3,377 nt. The TBHBV genomes comprised 3,149 nt, which varied by 4-74 (0.1-2.3%) nucleotide exchanges from each other. RBHBV and HBHBV diverged by 19% of their genomic nucleotide sequence from each other and 39% of their genomic nucleotide sequence from TBHBV. All bat viruses varied in their nucleotide sequences by at least 35% from sequences of any known hepadnavirus (Tables S3 and S4 ). As in all orthohepadnaviruses, the unique bat viruses contained four ORFs identifiable as the surface (S), polymerase (P), core (C), and X-ORFs (Fig. S2C) . The position of all ORFs in bat hepadnaviruses was similar to ORFs of the known members of the Orthohepadnavirus genus but clearly distinct from ORFs of duck hepatitis B virus, the prototype avihepadnavirus. The sizes of all predicted ORFs compared with homologs in prototype hepadnaviruses are shown in Fig. S2B . Details for the comparison of translated amino acid sequences of each predicted virus protein are provided in Tables S3 and S4 . The surface (S) protein genes encoded in the large open reading frame of all newly discovered hepadnaviral genomes contained a preS1, a preS2, and the S domain. The preS1 domain contained an N-myristoylation signal necessary for myristoylation at glycine-2 of preS1. Typical N-glycosylation sites within the preS2 and S domains were conserved, similar to HBV. Within the predicted antigenic SHBs loop, all eight essential cysteins for viral assembly, secretion, and infectivity (16) were present. Other than ORF organization, HBV and the bat hepadnaviruses also shared a similar location of the direct repeat (DR) sequences DR1 and DR2 involved in genome replication. In addition, secondary structure prediction highlighted the structural similarities between HBV and the bat hepadnaviruses in their e-loops, which serve as templates for the priming of reverse transcription of pregenomic RNA in all hepadnaviruses (Fig. S2D ).
According to a Bayesian phylogenetic analysis based on full ortho-and avihepadnavirus genomes, bat hepadnaviruses clustered within two highly supported monophyletic clades comprising the Old and New World bat viruses, respectively ( Fig. 2A) . The New World bat viruses formed a sister clade to all primate hepadnaviruses. Primate and New World bat viruses together were in sister relationship to all Old World bat viruses (RBHBV and HBHBV). Placement of the avihepadnaviruses as an outgroup to all orthohepadnaviruses resulted in a basal in-group bifurcation that separated the rodent viruses from all bat and primate viruses. A maximum likelihood (ML) analysis of the genus Orthohepadnavirus rooted accordingly yielded identical topologies with high statistical support (Fig. 2B) . The recently described Miniopterus bat hepadnavirus from Myanmar (17) clustered as a sister clade to the African bat viruses (RBHBV and HBHBV) in both Bayesian and ML tree reconstructions.
Infection Patterns and Serological Relatedness to HBV. In all five bats from which solid organs were available, viral DNA in tissues was quantified by real-time PCR (Fig. 3A) . Concentrations in liver tissue of the hipposiderid bats were significantly higher than concentrations in other organs or serum (t test, P < 0.01 for all). The highest virus concentration of 2.2 × 10 12 copies/g was observed in liver tissue. In the single R. alcyone bat, high concentrations were also observed in lung tissue. For New World bats, no organ specimens were available. However, viremia was measured in the blood of all five U. bilobatum, yielding concentrations comparable with or higher than concentrations observed in Old World bats (median = 7.3 × 10 10 copies/mL; range = 1.4 × 10 6 -2.7 × 10 11 ). Histopathology on available tissue samples showed few to moderate lymphocyte infiltrates and scant neutrophils/eosinophils in portal triads of hepadnavirus DNA-positive bats (Fig.  3B ). In situ hybridization using an RNA probe directed against the full genome of RBHBV yielded clear staining patterns suggestive of deposits of viral DNA within the nuclei and cytoplasm of hepatocytes in an RBHBV DNA-positive animal; these patterns were not seen in control animals or with an irrelevant probe ( Fig. 3C and Fig. S3A ).
For additional investigation of gene and protein functions, fulllength 1.1 infectious clones were generated for RBHBV, HBHBV, and TBHBV. For an assessment of serological reactivities in virus-infected bats, hepatoma cells were transfected with reconstructed RBHBV and HBHBV genome plasmids and stained with all available bat sera from the hepadnavirus DNA-positive species H. cf. ruber and R. alcyone in an immunofluorescence assay (IFA). Seroreactivities in New World bats were not assessed, because secondary antibodies against these species are not available. Antibody detection rates were high, with 18.4% in hipposiderid bats (9 of 49 animals) and 6.3% in rhinolophid bats (1 of 16 animals). Reactivity was observed in nuclei and cytoplasm, resembling typical reaction patterns of human sera directed against HBV core antigen (HBcAg) (Fig. 3D and Fig. S3 B and C) . IFA end-point titers ranged from 1:100 to 1:1,600, with a median of 1:400 in hipposiderid bats. The rhinolophid bat showed both viral DNA and a high titer against the homologous HBHBV (1:1,600). Of nine antibody-positive hipposiderid bats, two bats showed concomitant viral DNA and antibodies against the homologous RBHBV, seven bats showed antibodies only, and two bats showed viral DNA only. Table S5 provides details on DNA and antibody detection rates.
To assess serologic cross-recognition of the African bat hepadnaviruses, all IFA-positive specimens were also tested for antibody reactivity with the heterologous virus. The antibodypositive serum from the rhinolophid bat cross-recognized the hipposiderid bat virus antigens, and six of nine antibody-positive hipposiderid bat sera cross-recognized the rhinolophid bat virus antigens. Those three sera that did not show cross-reactivity had lower titers than the other sera (below 1:400).
The existence of anti-S antibodies was evaluated using cells transfected with plasmids, allowing expression of the large HBV surface protein (LHBs) antigens only. Of 10 IFA-reactive bat sera, only 1 hipposiderid serum showed detectable anti-S antibodies. This serum also reacted weakly with the LHBs proteins of the heterologous rhinolophid bat virus. In summary, these results suggested infection patterns similar to patterns seen in human HBV.
Poly-and monoclonal anti-HBV antibodies (pAb and mAb) revealed a particularly close serological relatedness between New World bat and primate viruses, concordant with phylogeny. For these viruses only, there was cross-reactivity between their main surface antigen determinants (S-gene amino acids 121-124), whereas cross-reactivities between primate and Old World bat viruses extended only to core proteins (Fig. 3E and Fig. S3C ).
To determine secretion of bat hepadnaviral surface proteins in the form of subviral particles (a hallmark of all Hepadnaviridae), the binding motif of the mAb HB1 reacting with a linear epitope of the antigenic determinant of the HBV surface proteins was used. To this end, the respective sites of the S-ORFs of RBHBV and HBHBV were substituted with the HB1 binding motif of the human genotype D by site-directed mutagenesis. In the case of TBHBV, a substitution was not necessary caused by the naturally occurring binding motif. The authentic S protein of TBHBV and the modified S proteins of RBHBV and HBHBV were secreted and detected by Western blotting in both the glycosylated and nonglycosylated forms (Fig. S3D ).
Replicative Capability in Human Cells. Because phylogenetic and serologic results suggested a zoonotic potential of bat hepadnaviruses, the 1.1 overlength expression vectors were tested for their capability to replicate after transfection into human hepatoma HepG2 cells. Because hepadnaviruses replicate through a reverse transcription (RT) step, the ability of the nucleoside RT inhibitor Entecavir to inhibit viral replication and thus, formation and secretion of viral particles was tested. The reverse transcriptase activity of all bat hepadnaviral constructs was inhibited by Entecavir in a dose-dependent manner comparable with HBV (Fig. S4A) . The IC 50 of Entecavir was below 10 nM for HBV and all bat hepadnaviruses. Because RT of HBV requires interaction of the viral polymerase and encapsidated pregenomic mRNA (immature core particle), these data proved pregenomic mRNA transcription and translation of functional polymerase and core gene products of bat hepadnaviruses in human cells.
Potential to Infect Human Cells. The N-terminal LHBs amino acid residues encompassing the preS1 domain are essential for infectivity of HBV. The unique bat hepadnaviruses showed high sequence identity within a short amino acid stretch (NPLGFFPDH) that is highly conserved within primate HBV, including WMHBV, but not rodent viruses, such as Woodchuck hepatitis virus (WHV) (Fig. S4B) . Within adjacent accessory domains (residues NPDWD and NKDHWPEANKVGVG), only TBHBV, but not the Old Word bat viruses, showed high levels of sequence identity to primate HBV. For functional investigations, synthetic myristoylated (myr) preS1 peptides derived from the three bat hepadnaviruses were tested for their potential to inhibit HBV infection of susceptible primary human hepatocytes (PHHs) and their widely used surrogate from Tupaias, T. belangeri primary hepatocyte (PTH). Inhibition of HBV infection was possible within nanomolar concentrations of all bat hepadnaviral myr-preS1 peptides (Fig. 4) . Myr-preS1 peptides derived from Old World bat hepadnaviruses (HBHBV and RBHBV) showed decreased inhibitory potential in PHH, with IC 50 values 50 to 60 times higher than values observed for TBHBV. An myr-preS1 peptide from WHV was used as a control and showed no reactivity at all. In PTH, myr-preS1 peptides from both HBHBV and TBHBV showed similar IC 50 values (Fig. S4C) . This observation correlated with the binding activity of these myr-preS1 peptides to PTH (Fig. S4D) . In summary, these data showed that myr-preS1 peptides of bat hepadnaviruses were able to bind to HBV-susceptible hepatocytes, thereby inhibiting HBV infection in vitro.
To further analyze the zoonotic potential of bat hepadnaviruses, hepatitis-Δ virus (HDV) particles pseudotyped with surface proteins of all three bat hepadnaviruses were generated (Fig.  S4E) . However, only HDV pseudotyped with surface proteins of TBHBV (HDV TBHBV ) was able to infect both PTH and PHH, a pattern similar to the pattern observed with HDV HBV (Fig.  5A ). Specificity of infection was shown by the addition of infection-interfering myr-preS1 peptides during HDV inoculation.
The infection-neutralizing potential of sera from persons successfully vaccinated against HBV with the standard HBV vaccine was assessed. Fig. 5B shows that two different human sera efficiently neutralized infection of PTH with HDV HBV but not HDV TBHBV . Addition of an mAb (HB1) directed against the antigenic loop of the S domain of HBV and TBHBV lowered infectivity in both cases. However, a strong, nearly complete neutralization was only achieved for HDV HBV . Another mAb (C20/2), recognizing a conformational epitope in the antigenic loop within the S domain of HBsAg, could efficiently neutralize HDV HBV but not HDV TBHBV , compatible with lower amino acid sequence identity of TBHBV in this domain.
The human sodium taurocholate cotransporting polypeptide (hNTCP) is a high-affinity receptor for HBV and HDV. Both HDV HBV and HDV TBHBV used hNTCP for infection of HepG2 cells transiently expressing this receptor molecule (Fig. 5C and Fig. S4F ). In both pseudotypes, the infection could be inhibited by specific myr-preS1 peptides. These results showed that, similar to HBV, the surface proteins of TBHBV supported infection of PTH and PHH by using the hNTCP receptor.
Discussion
We describe highly diversified HBV-related viruses in Old and New World bats that establish three unique orthohepadnavirus species according to the established sequence distance criteria (18) . All known primate, rodent, and avian hepadnaviruses can cause hepatitis in their hosts, with the possibility of symptom-free viremic carriage (19) . We confirmed hepatic tropism and high viremia in hepadnavirus-infected bats as well as inflammatory leukocyte infiltrations typical for hepatitis. We have not been able so far to conduct longitudinal sampling of HBV-positive bat populations, precluding any insight in disease progression and transmission. Transovarial transmission is typical for avihepadnaviruses, whereas rodent hepadnaviruses are predominantly transmitted perinatally; primate hepadnaviruses are transmitted both perinatally and sexually. The extent of perinatal transmission could affect the extent of chronic virus carriage, which is a main characteristic of all hepadnaviruses (19, 20) . We could not determine here the extent to which chronic infections occur in bats. High DNA detection rates speak in favor of prolonged courses of infection, but our finding of antibody-positive, DNA-negative Hipposideros bats together with a high seroprevalence of 18.4% indicate that bats can probably clear the infection. Detection of DNA-positive, antibody-negative bats indicates sampling before seroconversion, whereas concomitant detection of DNA and antibodies indicates delayed clearance just like in humans. Also, the lack of detectable anti-LHBs antibodies in all but one bat resembles human disease, because these antibodies can be precipitated by high concentrations of HB antigen in serum.
The possibility of a bat origin of primate hepadnaviruses enables speculations regarding their evolution. Primate HBV has only been detected in one monophyletic ape taxon, the Hominoidea superfamily, as well as the rather distantly related Woolly monkey, a New World primate (7, 9) . There is complete absence of detection in cercopithecoid monkeys (the Old World monkey sister clade to the Hominoidea) as well as lower nonsimiiform monkeys. This absence leaves doubts regarding virus-host cosegregation in primates and suggests a direct acquisition of HBV as a split-off from the stem lineage leading up to WMHBV by primates (21) . It should be noted that WMHBV has never been redetected in wild or captive animals, and serological studies have failed to detect antibodies against HBV in other New World monkeys (7) . WMHBV could, thus, have been acquired in captivity, and its actual host could have been either an Old or New World mammal. Of note, this animal could have been a bat, but the stem lineage leading up to primate viruses could also have been acquired from any other (probably mammalian) source.
Throughout Africa and to a much lesser extent, the Neotropical ecozone, the consumption of bats as wild game by humans is common practice (22) . We have, therefore, performed in-depth studies of the zoonotic potential of the described bat hepadnaviruses using several well-established techniques. It has been shown that infectivity and host tropism of HBV is determined by highly conserved amino acids of the preS1 domain and its myristic acid (19, 23) . In contrast to rodent hepadnaviruses, all bat hepadnaviruses showed nearly complete conservation of this relevant domain, and its functional importance was reflected in the potential of myr-preS1 peptides to compete with infection, similar to HBV in vitro and in vivo (24, 25) . However, we observed marked differences between primary human (PHH) and Tupaia (PTH) hepatocyte cultures. Although both cell culture systems showed similar susceptibilities to human serum-derived HBV infection, PHH revealed that preS1 peptides from TBHBV, but not HBHBV or RBHBV, reached IC 50 values similar to HBV peptides. The inhibitory potential of myr-preS1 peptides depends on their ability to block interaction of HBV with the newly discovered HBV receptor NTCP (26) . Although the Tupaia and hNTCP sequences are very similar (26), our results suggest that PHH should be used in binding and entry studies to accurately evaluate the zoonotic potential of newly discovered hepadnaviruses.
Analysis of infection competence using HDV pseudotypes suggested that only TBHBV surface proteins were capable of mediating infection similar to HBV. The incompatibility of RBHBV and HBHBV proteins was remarkable given the clear ability of their preS1 domains to bind hepatocytes and inhibit HBV infection. It should be mentioned that the work by Gudima et al. (27) reported infection of PHH, even with HDV particles pseudotyped with surface proteins from WHV (HDV WHV ), although WHV itself does not infect humans or chimpanzees. Gudima et al. (27) concluded that HDV WHV must infect PHH using a different receptor, because preS1 peptides from WHV, but not HBV, could inhibit HDV WHV infection. In contrast to that study, we show that HDV TBHBV and HDV HBV could both be inhibited by preS1 peptides of TBHBV and HBV with similar efficiencies. Furthermore, both HDV TBHBV and HDV HBV used the same HBV-specific receptor (hNTCP). Because HBHBV and RBHBV are replication-competent after transfection into human hepatoma cell lines, their restriction point might be the presence of a second (co-) receptor involved in HDV/HBV infection that might be highly species-specific. Characterization of the NTCP molecules of these two bat species might help elucidate whether HBHBV and RBHBV also use NTCP for hepatocyte entry.
Other than the preS1 domain, the antigenic loop of the S domain is another independent determinant for HDV and HBV infectivity (16, 28) . Among all bat hepadnaviruses, only TBHBV shared exactly the essential sequence C(R/K)TC within the antigenic loop with HBV and reacted with the mAb HB1 directed against this domain. These differences and others within the S domain might explain why TBHBV, but not the other bat hepadnaviruses, could infect PHH.
It should be mentioned that there are several limitations to our efforts to assess zoonotic potential. For instance, WMHBV can efficiently infect other New World primates but not Old World primates in vivo (29) , whereas recombinant HDV WMHBV viruses can infect human and chimpanzee primary hepatocytes (30) . One might, therefore, argue that our surrogate assays may not properly reflect the in vivo situation. However, additional proof of zoonotic potential would require inoculation of chimpanzees, which is not ethical given the expected severity of infection. Severe combined immunodeficiency mice transgenic for urokinase-type plasminogen activator (uPA/SCID) mice engrafted with human hepatocytes could serve as alternative models (31), but they would have to be validated by comparisons with chimpanzees before application on TBHBV, which is still distantly related to HBV and thus, might behave differently in this model. Another limitation arises from the use of recombinant HDV/bat hepadnaviruses for infection and inhibition studies. However, because the recovery of homologous recombinant orthohepadnaviruses in sufficient amount is technically difficult, recombinant HDV/hepadnaviruses are widely accepted as surrogates (19, 27, 30) .
In conclusion, among the three unique hepadnavirus species described in this report, we have evidence for a zoonotic potential for one of them, the New World bat-associated TBHBV. The lack of neutralization of this virus by high-titered anti-HBs sera from vaccinated individuals matches the observation of occasional failure of the standard vaccine, even against heterologous human HBV genotypes (32) . Elimination of HBV from global circulation in humans is conceivable within several generations (3), but a revised vaccine formulation, including full LHBs or at least the critical preS1 domain, could become necessary to that end (33) . Future vaccination concepts might also have to integrate considerations of the zoonotic potential of primate and nonprimate hepadnaviruses (2) . It is unclear whether bat hepadnaviruses impose an ongoing risk of zoonotic human infections, but it should be considered that these viruses are genetically sufficiently distinct from HBV to go undetected in routine serological and molecular screening programs. Of note, access of humans to such HBV routine diagnostic programs cannot be deemed likely in the remote tropical areas from which these bats were sampled, highlighting the need for screening of human and nonhuman primate sera from these areas by broadly reactive diagnostic methods. Whereas ape populations are decreasing because of habitat exploitation on a global scale, bats can adapt to anthropogenic influence in multiple ways, leading to modifications of social structure, pathogen richness, and exposure to humans. We are only beginning to understand the role of bats as reservoirs of zoonotic viruses, emphasizing the importance of viral surveillance and the integration of ecological concepts into infectious disease epidemiology (34) .
Materials and Methods
Sampling, Hepadnavirus Detection, and Characterization. Bats were caught as described previously (4) . Permits are given in SI Materials and Methods.
Purification, detection, and characterization of viral DNA were done as described previously and in SI Materials and Methods (4, 15, 35) . Phylogenetic analyses were done using MrBayes (36) and PhyML (37) .
HBV Constructs and Infection Experiments. Overlength constructs (1.1), surface expression vectors, and HDV pseudoparticles were generated as described previously (38) (39) (40) . PHH and PTH infection, HBsAg detection, and infection of cells expressing the hNTCP were done as described before (41) and in SI Materials and Methods.
